Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Envafolimab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Glenmark, Jiangsu Alphamab, and 3D Medicines Sign License Agreement for KN035
Details : Glenmark is responsible for developing, registering, and commercializing KN035 (envafolimab) outside of China for MSI-H or dMMR advanced solid tumors in previously treated adults.
Brand Name : KN035
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : Envafolimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?